Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH ...

Please provide your email address to receive an email when new articles are posted on . Experts recommend confirming MASH diagnosis by assessing steatosis via ultrasound or FibroScan. MRI-proton ...

Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...

Management expects fourth quarter gross to net to be at the midpoint of the 20% to 30% range previously discussed. Starting in the first quarter and through 2026, "we expect our gross to net impact to ...

Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra ...

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach ...

Credit: Madrigal Pharmaceuticals. The approval was based on data from the pivotal phase 3 MAESTRO-NASH study, which included patients with biopsy-proven NASH and fibrosis who were on stable doses of ...

Madrigal Pharmaceuticals reported strong first-quarter revenue growth driven by Rezdiffra adoption while expanding its MASH ...